XLO - NASDAQ
Xilio Therapeutics, Inc.
$8.46
-0.71%Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
At a Glance
Live Snapshotxlo
Cash and Short Term Investments
Last Annual Value
137.53M
3-Year CAGR
5%
5-Year CAGR
48%
10-Year CAGR
11%
Xilio Therapeutics, Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Xilio Therapeutics, Inc. NASDAQ:XLO | 137.53M | 45.4% | -7.0% | N/A | |
 PDS Biotechnology Corporation NASDAQ:PDSB | 26.71M | -22.1% | -16.4% | -12.9% | |
 OnKure Therapeutics, Inc. NASDAQ:OKUR | 59.05M | 25.5% | -16.7% | N/A | |
 Actinium Pharmaceuticals, Inc. AMEX:ATNM | 72.90M | -1.7% | -1.3% | 13.5% | |
 Kezar Life Sciences, Inc. NASDAQ:KZR | 71.88M | -29.1% | -19.2% | 22.1% | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 77.84M | -16.9% | -16.4% | N/A |
Xilio Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your XLO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.